Unity Bio (UBX) Stock Forecast, Price Target & Predictions
UBX Stock Forecast
Unity Bio stock forecast is as follows: a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
UBX Analyst Ratings
According to 4 Wall Street analysts, Unity Bio's rating consensus is 'Buy'. The analyst rating breakdown for UBX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 22, 2024 | Rodman & Renshaw | - | Buy | Initialise |
| Apr 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Nov 16, 2023 | Wedbush | - | Outperform | Upgrade |
| Aug 15, 2022 | Citigroup | Buy | Buy | Hold |
Unity Bio's last stock rating was published by Rodman & Renshaw on Aug 22, 2024. The company Initialise its UBX rating from "null" to "Buy".
Unity Bio Financial Forecast
Unity Bio Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| Revenue | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| # Analysts | - | - | - |
| Surprise % | - | - | - |
Unity Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. UBX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Unity Bio EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EBITDA | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
undefined analysts predict UBX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Unity Bio's previous annual EBITDA (undefined) of $NaN.
Unity Bio Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| Net Income | - | - | - |
| Avg Forecast | $-6.73M | $-6.79M | $-7.77M |
| High Forecast | $-6.73M | $-6.79M | $-7.77M |
| Low Forecast | $-6.73M | $-6.79M | $-7.77M |
| Surprise % | - | - | - |
Unity Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. UBX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Unity Bio SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| SG&A | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
Unity Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to UBX last annual SG&A of $NaN (undefined).
Unity Bio EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EPS | - | - | - |
| Avg Forecast | $-0.40 | $-0.40 | $-0.46 |
| High Forecast | $-0.40 | $-0.40 | $-0.46 |
| Low Forecast | $-0.40 | $-0.40 | $-0.46 |
| Surprise % | - | - | - |
According to undefined Wall Street analysts, Unity Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to UBX previous annual EPS of $NaN (undefined).
Unity Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| UBX | Unity Bio | $1.45 | $80.00 | 5417.24% | Buy |
| OVID | Ovid Therapeutics | $1.02 | $7.33 | 618.63% | Buy |
| NTLA | Intellia Therapeutics | $19.72 | $119.16 | 504.26% | Buy |
| PRME | Prime Medicine | $3.55 | $17.25 | 385.92% | Buy |
| EDIT | Editas Medicine | $3.59 | $17.00 | 373.54% | Buy |
| HRTX | Heron Therapeutics | $1.80 | $7.00 | 288.89% | Buy |
| VERV | Verve Therapeutics | $5.60 | $21.50 | 283.93% | Buy |
| DRMA | Dermata Therapeutics | $1.58 | $6.00 | 279.75% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.22 | $7.00 | 215.32% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| BEAM | Beam Therapeutics | $23.31 | $63.00 | 170.27% | Buy |
| NUVB | Nuvation Bio | $2.79 | $7.00 | 150.90% | Buy |
| NXTC | NextCure | $1.42 | $3.00 | 111.27% | Buy |
| AVIR | Atea Pharmaceuticals | $3.60 | $6.88 | 91.11% | Hold |
| RXRX | Recursion Pharmaceuticals | $5.92 | $9.67 | 63.34% | Hold |
| RNA | Avidity Biosciences | $40.46 | $50.00 | 23.58% | Buy |
| CNTB | Connect Biopharma | $1.25 | $1.50 | 20.00% | Buy |
| EXAI | Exscientia | $4.90 | $5.00 | 2.04% | Hold |
| HOOK | HOOKIPA Pharma | $4.74 | $3.00 | -36.71% | Buy |
UBX Forecast FAQ
Is Unity Bio a good buy?
Yes, according to 4 Wall Street analysts, Unity Bio (UBX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of UBX's total ratings.
What are Unity Bio's analysts' financial forecasts?
UBX's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-21.284M (high $-21.284M, low $-21.284M), average SG&A $0 (high $0, low $0), and average EPS is $-1.266 (high $-1.266, low $-1.266).